• Cleveland BioLabs Inc., of Buffalo, N.Y., and its subsidiary Incuron LLC, of Moscow, said a study demonstrating that CBL0137 counteracted tumor formation in a mouse spontaneous breast cancer model was published online in Cancer Prevention Research.